Actionable news
0
All posts from Actionable news
Actionable news in IMDZ: IMMUNE DESIGN Corp,

Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016

SEATTLE and SOUTH SAN FRANCISCO, Calif., Apr 20, 2016 (GLOBE NEWSWIRE via COMTEX) --

  • Curative Efficacy and Anti-tumor Immunity Demonstrated with Intratumoral Administration of IL-12 by a ZVexTM Vector
  • Systemic Anti-tumor Immunity Demonstrated with Intratumoral G100

Immune Design IMDZ, -7.96% a clinical-stage immunotherapy company focused on oncology, today announced the presentation of new preclinical data demonstrating broad anti-tumor activity of its ZVex [TM] platform and further evidence of the anti-tumor activity of G100, both via intratumoral administration. Results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.

"These AACR data highlight the multi-faceted approaches that Immune Design is employing to generate a therapeutic anti-tumor immune response," said Jan ter Meulen, MD, PhD, Chief Scientific Officer at Immune Design. "The results presented support for the first time the potential intratumoral applicability of Immune Design's dendritic-cell targeting platform, ZVex, beyond its current use to generate an antigen-specific immune response via systemic administration. Moreover, we presented additional data supporting the ongoing clinical development of G100 as a novel approach to intratumoral immunization."

Immune Design presented data describing the intratumoral administration of a ZVex Interleukin-12 (IL-12) vector to generate localized, intratumoral expression of IL-12. IL-12 is one of the most potent modulators of innate and adaptive immune response, but its use in the clinical setting has been limited due to toxicity when administered systemically. Results presented demonstrate strong local and systemic anti-tumor efficacy of the ZVex/IL-12 across multiple pre-clinical tumor models, including synergy when co-administrated with anti-CTLA-4 and GLA, Immune Design's synthetic TLR4 agonist, Glucopyranosyl Lipid A, the core of Immune Design's GLAAS [TM] platform. The AACR presentation was titled "Intratumoral expression of IL-12 from a dendritic cell-targeting chimeric lentiviral vector from the ZVex platform cures established tumors in multiple models and induces systemic anti-tumor responses" (Abstract #4884).

In addition, Immune Design presented data highlighting the ability of its G100 product candidate, comprised of GLA in a stable emulsion, to modulate the tumor microenvironment and trigger local and systemic immune responses following its direct injection in a murine lymphoma model. G100 induced broad pro-inflammatory cytokine and chemokine responses, while also upregulating activating genes in immune cells, leading to the switch from a "cold" to a "hot" tumor state. In addition, the upregulation of checkpoints...


More